Clinical Trial Search

Primary: Dihydrotestosterone (DHT) Concentration in Benign Prostate Tissue After a Combination Drug Treatment Based on Genotype Status — 9.066; 5.917; 9.345 nM

Primary: Wave Reflection Magnitude — 0.38; 0.44; 0.37 dimensionless ratio

Primary: Fluoride Concentration in Dental Biofilm Fluid at Baseline — 0.24; 0.22 parts per million (ppm) of fluoride — p=0.8412

Primary: Endogenous Glucose Production (EGP) — 4.99; 5.02; 6.82; 5.52 umol/kg/min

Primary: Number of Adverse Events — 0; 1 events

Primary: Combined Clinically Significant Postoperative Pancreatic Fistula and Intra-abdominal Abscess — 8 Participants

Primary: Factor IX Activity Levels — 30.6 Factor IX activity (%)

Primary: Number of Participants Experiencing Adverse Events — 5; 4; 13; 10 Participants

Primary: The Primary Outcome Measure Was Any Response at 6 Months — 178; 173 Participants — p=<0.05

Primary: Prostate-specific Antigen (PSA) Response — 48; 48 percentage of participants — p=.6789

Primary: Umber of Participants With Major Adverse Cardiac and Cerebrovascular Events (MACCE) — 47; 54 Participants

Primary: Part 2: Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) — 91.5; 95.4; 24.8; 38.0 Percentage of Participants

Primary: Aberrant Behavior Checklist-Community Fragile X Factor Structure (ABC-C FXS) Social Avoidance Subscale - Full Analysis Set — -2.68; -2.29 change in score — p=0.321

Primary: Number of Participants With Receipt of Dental Care-restoration or Extraction of at Least One Tooth at Final Exam — 68; 76; 8; 14 Participants — p=<0.05

Primary: Grade II-IV Acute GVHD — 30 percentage of participants